drugset / Trial / NCT00806598
Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if combining the drugs thymoglobulin, methylprednisolone, cyclosporine, and G-CSF (NeupogenTM or NeulastaTM ) can help to control severe aplastic anemia (AA) or hypoplastic myelodysplastic syndrome (MDS). The safety of this combination therapy will also be studied.
Timeline
- Start
- 2005-05
- Primary completion
- 2012-06
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Subject | G-CSF | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 3.5 mg/kg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 1 mg/kg | Intravenous |